ACAD
34.3
-0.68
-1.94%
AEMD
4.96
-0.15
-2.94%
APRI
0.342
-0.008
-2.3163%
ARNA
1.73
-0.01
-0.57%
ATEC
8.21
-0.42
-4.87%
CNAT
2.1
-0.01
-0.47%
CRXM
0.24
-0.03
-10.70%
CYTX
2.04
-0.08
-3.77%
DXCM
93.16
-0.75
-0.80%
GNMK
11.56
-0.14
-1.20%
HALO
11.98
-0.11
-0.91%
ILMN
178.47
-0.86
-0.48%
INNV
0.29
+0.01
+3.5357%
INO
9.44
-0.06
-0.63%
ISCO
1.84
-0.06
-3.16%
ISIS
57.56
0.00
0.00%
LGND
113.09
-2.69
-2.32%
LPTN
3.83
-0.06
-1.54%
MBVX
4.16
-0.56
-11.86%
MEIP
1.71
+0.02
+1.18%
MNOV
7.47
+0.37
+5.21%
MRTX
6.2
+0.32
+5.44%
MSTX
0.123
-0.004
-3.454%
NBIX
53.25
-0.69
-1.28%
NUVA
66.15
-0.62
-0.93%
ONCS
1.77
-0.01
-0.56%
ONVO
3.91
-0.06
-1.51%
OREX
3.24
-0.22
-6.36%
OTIC
17.13
-0.52
-2.95%
QDEL
22.17
-0.54
-2.38%
RCPT
231.96
0.00
0.00%
RGLS
3.42
-0.03
-0.87%
RMD
63.59
+0.34
+0.54%
SPHS
3.22
+0.26
+8.78%
SRNE
7.67
-0.1
-1.29%
TROV
4.63
-0.16
-3.34%
VICL
3.19
-0.06
-1.85%
VOLC
18
0.00
0.00%
ZGNX
10.35
-0.1
-0.96%
ACAD
34.3
-0.68
-1.94%
AEMD
4.96
-0.15
-2.94%
APRI
0.342
-0.008
-2.3163%
ARNA
1.73
-0.01
-0.57%
ATEC
8.21
-0.42
-4.87%
CNAT
2.1
-0.01
-0.47%
CRXM
0.24
-0.03
-10.70%
CYTX
2.04
-0.08
-3.77%
DXCM
93.16
-0.75
-0.80%
GNMK
11.56
-0.14
-1.20%
HALO
11.98
-0.11
-0.91%
ILMN
178.47
-0.86
-0.48%
INNV
0.29
+0.01
+3.5357%
INO
9.44
-0.06
-0.63%
ISCO
1.84
-0.06
-3.16%
ISIS
57.56
0.00
0.00%
LGND
113.09
-2.69
-2.32%
LPTN
3.83
-0.06
-1.54%
MBVX
4.16
-0.56
-11.86%
MEIP
1.71
+0.02
+1.18%
MNOV
7.47
+0.37
+5.21%
MRTX
6.2
+0.32
+5.44%
MSTX
0.123
-0.004
-3.454%
NBIX
53.25
-0.69
-1.28%
NUVA
66.15
-0.62
-0.93%
ONCS
1.77
-0.01
-0.56%
ONVO
3.91
-0.06
-1.51%
OREX
3.24
-0.22
-6.36%
OTIC
17.13
-0.52
-2.95%
QDEL
22.17
-0.54
-2.38%
RCPT
231.96
0.00
0.00%
RGLS
3.42
-0.03
-0.87%
RMD
63.59
+0.34
+0.54%
SPHS
3.22
+0.26
+8.78%
SRNE
7.67
-0.1
-1.29%
TROV
4.63
-0.16
-3.34%
VICL
3.19
-0.06
-1.85%
VOLC
18
0.00
0.00%
ZGNX
10.35
-0.1
-0.96%
Home » John Finn Biography

John Finn Biography

Dr. Finn holds a B.S. in chemistry from Villanova University and a Ph.D. in organic chemistry from the University of Illinois. He spent the first ten years of his industrial career as doing optimization chemistry for American Cyanamid. In 1995, He moved to Synaptic Pharmaceutical as an associate director of medicinal chemistry at Synaptic Pharmaceutical focusing on drugs targeting novel GPCR targets. From 1998 to 2004, Dr. Finn held various leadership positions at Cubist Pharmaceuticals and Elitra Pharmaceuticals, two biotech companies focusing on novel antibacterial agents. Dr. Finn has served as the chief scientific officer of Trius since February 2007 and is a co-founder of our company. From July 2004 to February 2007, he served as the president.